Latest Biosimilar Stories
In an upcoming webinar from Atlantic Information Services, participants will learn how to manage specialty drug coupons without compromising patient access. Washington,
New research report “The Future of Biosimilars: mapping critical uncertainties and the impact of future events” by FirstWord is now available at MarketPublishers.com. London,
DUBLIN, May 20, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/9trl4k/11th_annual)
NEUDORF SPECIAL ECONOMIC ZONE, ST.
PASADENA, Calif., May 19, 2014 /PRNewswire/ -- Meditope Biosciences, Inc., a biotechnology company developing novel
REDWOOD CITY, Calif., May 19, 2014 /PRNewswire/ -- Coherus BioSciences, Inc.
DUBLIN, May 13, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has received final approval from the U.S.
REDWOOD CITY, Calif., May 12, 2014 /PRNewswire/ -- Coherus Biosciences, Inc. ("Coherus"), is pleased to announce the appointment of Lisa M. Bell, Ph.D.
DUBLIN, May 12, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Valeant Pharmaceuticals International to settle all outstanding patent
Many pharmaceutical manufacturers will likely derive sales volumes from biological drugs, while also contending with the entrance of biosimilar, or generic biological drugs, into the market.
- An imitative word; an onomatopoetic word.